CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses
/in Dendritic Cells, International PublicationsRestoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment
/in Dendritic Cells, International PublicationsNatural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer
/in Cervical Cancer, Dendritic Cells, International PublicationsPerspectives for immunotherapy in glioblastoma treatment
/in Dendritic Cells, Glioblastoma, International PublicationsEmerging treatment strategies for glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusAntigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression
/in Dendritic Cells, International PublicationsDendritic cell cancer vaccines: from the bench to the bedside
/in Dendritic Cells, International PublicationsEnhancing dendritic cell-based vaccination for highly aggressive glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsLong-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
/in Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus, Prostate Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer